Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Oncogenesis
SJR: 0.946 SNIP: 0.503 CiteScore™: 2

ISSN Imprimir: 0893-9675
ISSN En Línea: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2017024506
pages 195-218

Histone Acetyltransferases in Cancer: Guardians or Hazards?

Christina Demetriadou
University of Cyprus, Department of Biological Sciences, Nicosia, Cyprus
Antonis Kirmizis
University of Cyprus, Department of Biological Sciences, Nicosia, Cyprus


Histone acetyltransferases (HATs) catalyzing N-epsilon-lysine or N-alpha-terminal acetylation on histone and non-histone substrates are important epigenetic regulators controlling gene expression and chromatin structure. Deregulation of these enzymes by genetic or epigenetic alterations accompanied by defects in gene transcription have been implicated in oncogenesis. Therefore, these enzymes are considered promising therapeutic targets, offering new horizons for epigenetic cancer therapy. However, recent observations suggest that these enzymes function as both oncogenes and tumor suppressors. In this review, we present the current evidence demonstrating that individual HATs can either prevent cancer cell proliferation or drive malignant transformation depending on the molecular context and cancer type. We therefore advocate that future therapeutic interventions targeted toward these enzymes should carefully consider the fact that HATs commonly have a two-sided role in carcinogenesis.

Articles with similar content:

Mechanisms of Raf-1 Kinase Inhibitor Protein Dysregulation in Triple-Negative Breast Cancers and Identification of Possible Novel Therapeutic Approaches for These Tumors
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 3-4
Manuela Labbozzetta, Nicoletta Vivona, Paola Poma, Monica Notarbartolo, Natale D'Alessandro
Histone Deacetylases and Cancer-Associated Angiogenesis: Current Understanding of the Biology and Clinical Perspectives
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 1-2
Vincent Castronovo, Andrei Turtoi, Paul Peixoto, Akeila Bellahcene
New Prospectives of Prostate Cancer Gene Therapy: Molecular Targets and Animal Models
Critical Reviews™ in Eukaryotic Gene Expression, Vol.11, 2001, issue 1-3
Chia-Ling Hsieh, Leland W. K. Chung
Arsenic-Mediated Cellular Signal Transduction, Transcription Factor Activation, and Aberrant Gene Expression: Implications in Carcinogenesis
Journal of Environmental Pathology, Toxicology and Oncology, Vol.21, 2002, issue 4
Krystyna Frenkel, Chengfeng Yang
Raf Kinase Inhibitory Protein (RKIP) as a Metastasis Suppressor: Regulation of Signaling Networks in Cancer
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 6
Marsha Rich Rosner, Ali E. Yesilkanal